Percutaneous microwave ablation versus surgical resection for ovarian cancer liver metastasis

Zhuo, Shuiqing; Zhou, Jian; Ruan, Guangying; Zeng, Sihui; Ma, Huali; Xie, Conghua; An, Chao

doi:10.1080/02656736.2019.1706767

Cited by 7 publications

(4 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Similar results to breast cancer were achieved in radically resected ovarian cancer liver metastases with 5-and 10-year survival rates of 41% and 21%, respectively, and kidney cancer liver metastases with 5-and 10-year overall survival rates of 39% and 18%, respectively. These results are confirmed by others (Bauschke et al 2021;Zhuo et al 2020).…”

Section: Discussionsupporting

confidence: 89%

Surgical treatment of liver metastases from non-colorectal non-neuroendocrine carcinomas

Bauschke

Altendorf-Hofmann

Homman

et al. 2021

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

Introduction In the literature, results after surgical treatment of non-colorectal non-neuroendocrine liver metastases (NCNNLM) are reported that are often inferior to those from colorectal liver metastases. The selection of patients with favorable tumor biology is currently still a matter of discussion. Materials/methods The retrospective data analysis was based on data that were collected for the multicenter study “Role of surgical treatment for non-colorectal liver metastases” in county Thuringia. Results For the study, 637 patients were included from 1995 to 2018. 5 and 10-year survival of R0 resected patients were 33% and 19%, respectively. In the multi-variate analysis of the entire group, sex, timing, disease-free interval, number of metastases, R-classification as well as lymph node status of the primary lesion showed an independent statistical influence on the 5-year survival. In the group of R0 resected patients, disease-free interval, number of metastases and lymph node status of the primary lesion influenced the 5-year survival in the multi-variate analysis. In kidney malignancies, R-classification, timing and number of liver metastases were statistically significant in the multi-variate analysis of the 5-year survival, in mamma carcinomas only the R-classification. Conclusion The Adam score identifies some risk factors which influence prognosis in most but not in all tumor entities. For kidney cancer and breast cancer it can be simplified.

show abstract

Section: Discussionsupporting

confidence: 89%

Surgical treatment of liver metastases from non-colorectal non-neuroendocrine carcinomas

Bauschke

Altendorf-Hofmann

Homman

et al. 2021

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

show abstract

“…Zhuo et al analyzed the survival difference of 29 ovarian cancer patients with liver metastases receiving microwave ablation (MWA) or surgical resection (SR). And no significant difference was seen between the two groups (5 year OS rate: SR vs. MWA, 64.3% vs. 51.3%, P = 0.198) (32). Ailbhe et al compared the clinical characteristics and survival between ovarian cancer patients with liver parenchymal invasion (LPI) from peritoneal metastases and those with hematogenous liver metastases (HLM).…”

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

A Population-Based Study on Liver Metastases in Women With Newly Diagnosed Ovarian Cancer

Zhao

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

The purpose of this study was to analyze the incidence, clinical characteristics, prognostic factors and survival of ovarian cancer patients with liver metastases upon initial diagnosis. Methods: Patients with ovarian cancer liver metastases upon initial diagnosis between 2010 and 2016 were identified from the Surveillance, Epidemiology, and End Results (SEER) database. Univariate and multivariate logistic regression was performed to identify the predictors of the presence of liver metastases in newly diagnosed ovarian cancer patients. Overall survival (OS) was assessed using the Kaplan-Meier method and logrank test. Univariate and multivariate Cox regression was conducted to determine the independent prognostic factors for OS. Results: A total of 1,744 ovarian cancer patients with liver metastases was identified from the SEER database, accounting for 6.7% of the entire ovarian cancer patients. As to the unique distant organ provided by SEER, liver was the most common metastatic site of ovarian cancer (4.65%). Age, race, laterality, histology, pathological grade, extrahepatic sites, stage of tumor were the predictors of the presence with liver metastases revealed by multivariable logistic regression model. Median OS for the patients with liver metastases at initial diagnosis of ovarian cancer was 16.0 months. Multivariate Cox regression model confirmed race, histology, extrahepatic metastatic sites, surgery and marital status were independent prognostic factors for OS. Conclusion: The study provided population-based estimates of the incidence and prognosis of newly diagnosed ovary cancer patients with liver metastases, which could be potentially used for the risk assessment and individualized treatment.

show abstract

“…Лекции Reviews. Lectures печени и длительный интервал времени без прогрессирования были значимыми факторами, коррелировавшими с благоприятным исходом пациентов с раком яичников и метастазами в печень [24].…”

Section: цель работыunclassified

Prognostic Factors for Ovarian Cancer (Review)

Журман¹

2022

Евразийский Онкологический Журнал

View full text Add to dashboard Cite

Рак яичников является одним из наиболее распространенных злокачественных новообразований у женщин, характеризуется низкими показателями 5-летней выживаемости – ниже 45,0%. В большинстве случаев рак яичников диагностируется на поздних стадиях (III–IV стадия по FIGO) из-за скрытой клинической картины заболевания и неэффективных методов ранней диагностики, что приводит к неблагоприятному исходу заболевания. Современные стандарты лечения у пациентов с распространенным раком яичников включают циторедуктивную хирургию и химиотерапию с использованием препаратов платины и таксанов. Несмотря на высокую чувствительность заболевания к химиотерапии, у пациентов с III–IV стадией рака яичников в итоге развивается рецидивирующее заболевание, устойчивое к химиотерапии.Факторы, которые способны повлиять на исход лечебных мероприятий при раке яичников, подразделяются на группы, связанные с пациентом (возраст, наличие сопутствующей патологии, общее состояние пациента), с биологическими характеристиками опухоли (стадия процесса, гистологический тип, наличие или отсутствие отдаленных метастазов), с результатами клинико-лабораторных методов исследования и выбранной тактики лечения.Прогнозирование эффективности лечения на всех этапах терапии будет способствовать повышению показателей общей выживаемости, выживаемости без прогрессирования и качества жизни пациентов с раком яичников I–IV стадии. Ovarian cancer (OC) is one of the most common malignant neoplasms of the female genital tract, characterized by a high mortality rate (50%), a decrease in overall survival (OS) and progression-free survival (PFS) of the process.Factors that can affect the outcome of therapeutic measures in OC are subdivided into groups associated with the patient (age, presence of concomitant pathology, general condition of the patient’s body), with the biological characteristics of the tumor (size, stage of the process, histological type, presence or absence of metastasis), with the results of clinical and laboratory research methods and the selected management tactics.Accordingly, taking into account these factors, a personalized approach to the general management of patients can be developed with the choice of the preferred method (surgical treatment, chemotherapy, radiation therapy, hormonal or targeted therapy).Predicting the effectiveness of treatment at all stages of therapy will contribute to an increase in OS, PFS and quality of life in stage I–IV patients.

show abstract

Percutaneous microwave ablation versus surgical resection for ovarian cancer liver metastasis

Cited by 7 publications

References 28 publications

Surgical treatment of liver metastases from non-colorectal non-neuroendocrine carcinomas

Surgical treatment of liver metastases from non-colorectal non-neuroendocrine carcinomas

A Population-Based Study on Liver Metastases in Women With Newly Diagnosed Ovarian Cancer

Prognostic Factors for Ovarian Cancer (Review)

Contact Info

Product

Resources

About